Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

Compare

1,433 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TNDM Analyst Ratings

Moderate Buy

7 Buy

13 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Tandem

Diabetes Care

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TNDM Stock 12 Month Forecast

Average Price Target

$19.53

▲(39.50% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $19.53 with a high forecast of $51.00 and a low forecast of $12.00. The average price target represents a 39.50% change from the last price of $14.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","52":"$52","21.25":"$21.3","31.5":"$31.5","41.75":"$41.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,21.25,31.5,41.75,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.41,15.37846153846154,18.346923076923076,21.315384615384616,24.283846153846156,27.252307692307696,30.220769230769232,33.189230769230775,36.157692307692315,39.126153846153855,42.094615384615395,45.063076923076935,48.03153846153846,{"y":51,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.41,12.957692307692309,13.505384615384616,14.053076923076924,14.600769230769231,15.14846153846154,15.696153846153848,16.243846153846157,16.79153846153846,17.33923076923077,17.88692307692308,18.434615384615384,18.982307692307693,{"y":19.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.41,12.378461538461538,12.346923076923076,12.315384615384616,12.283846153846154,12.252307692307692,12.22076923076923,12.18923076923077,12.157692307692308,12.126153846153846,12.094615384615384,12.063076923076924,12.031538461538462,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.06,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.14,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.98,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.24,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.78,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.41,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$51.00

Average Price Target$19.53

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Joanne Wuensch

Citi

$11→$15

Hold

7.14%

Upside

Reiterated

10/07/25

Tandem Diabetes price target raised to $15 from $11 at CitiTandem Diabetes price target raised to $15 from $11 at Citi

Lila Implantra

TR | OpenAI - 4o

$12→$13

Hold

-7.14%

Downside

Reiterated

10/03/25

AI Generated ArticleAI Generated Article

William Plovanic

Canaccord Genuity

$24

Buy

71.43%

Upside

Reiterated

09/29/25

Tandem Diabetes Care (TNDM) Gets a Buy from Canaccord Genuity

Patrick Wood

Morgan Stanley

$13

Hold

-7.14%

Downside

Reiterated

09/10/25

Tandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold Rating

Suraj Kalia

Oppenheimer

$44→$22

Buy

57.14%

Upside

Initiated

09/08/25

Tandem Diabetes assumed with an Outperform at OppenheimerTandem Diabetes assumed with an Outperform at Oppenheimer

Shagun Singh Chadha

RBC Capital

$25

Buy

78.57%

Upside

Reiterated

08/19/25

Tandem Diabetes Care (TNDM) Gets a Buy from RBC Capital

Matthew Taylor

Jefferies

―

Buy

―

Reiterated

08/18/25

We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.

Josh Jennings

TD Cowen

$20

Buy

42.86%

Upside

Reiterated

08/15/25

TD Cowen Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)

Ken Leon

CFRA

$33→$22

Hold

57.14%

Upside

Reiterated

08/11/25

CFRA Reaffirms Their Hold Rating on Tandem Diabetes Care (TNDM)CFRA analyst Kenneth Leon lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $22.00 (from $33.00) while maintaining a Hold rating.

Frank Takkinen

Lake Street

$12

Hold

-14.29%

Downside

Initiated

08/11/25

Tandem Diabetes downgraded to Hold from Buy at Lake StreetTandem Diabetes downgraded to Hold from Buy at Lake Street

Richard Newitter

Truist Financial

$17→$14

Hold

0.00%

Upside

Reiterated

08/07/25

Tandem Diabetes Care (TNDM) Receives a Hold from Truist Financial

Jeff Johnson

Robert W. Baird

$24→$16

Hold

14.29%

Upside

Reiterated

08/07/25

Robert W. Baird Remains a Hold on Tandem Diabetes Care (TNDM)

Matt Miksic

Barclays

$53→$51

Buy

264.29%

Upside

Reiterated

08/07/25

Tandem Diabetes Care (TNDM) Receives a Buy from Barclays

Christopher Pasquale

Nephron

$14

Hold

0.00%

Upside

Downgraded

08/07/25

Tandem Diabetes downgraded to Hold from Buy at Nephron ResearchTandem Diabetes downgraded to Hold from Buy at Nephron Research

Mike Kratky

Leerink Partners

$38→$32

Buy

128.57%

Upside

Reiterated

08/07/25

Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Joanne Wuensch

Citi

$11→$15

Hold

7.14%

Upside

Reiterated

10/07/25

Tandem Diabetes price target raised to $15 from $11 at CitiTandem Diabetes price target raised to $15 from $11 at Citi

Lila Implantra

TR | OpenAI - 4o

$12→$13

Hold

-7.14%

Downside

Reiterated

10/03/25

AI Generated ArticleAI Generated Article

William Plovanic

Canaccord Genuity

$24

Buy

71.43%

Upside

Reiterated

09/29/25

Tandem Diabetes Care (TNDM) Gets a Buy from Canaccord Genuity

Patrick Wood

Morgan Stanley

$13

Hold

-7.14%

Downside

Reiterated

09/10/25

Tandem Diabetes Care: Strategic Initiatives and Market Challenges Justify Hold Rating

Suraj Kalia

Oppenheimer

$44→$22

Buy

57.14%

Upside

Initiated

09/08/25

Tandem Diabetes assumed with an Outperform at OppenheimerTandem Diabetes assumed with an Outperform at Oppenheimer

Shagun Singh Chadha

RBC Capital

$25

Buy

78.57%

Upside

Reiterated

08/19/25

Tandem Diabetes Care (TNDM) Gets a Buy from RBC Capital

Matthew Taylor

Jefferies

―

Buy

―

Reiterated

08/18/25

We reiterate our Buy rating on shares of DXCM, ABT, PODD, and TNDM, with a Hold rating on MDT.

Josh Jennings

TD Cowen

$20

Buy

42.86%

Upside

Reiterated

08/15/25

TD Cowen Reaffirms Their Buy Rating on Tandem Diabetes Care (TNDM)

Ken Leon

CFRA

$33→$22

Hold

57.14%

Upside

Reiterated

08/11/25

Frank Takkinen

Lake Street

$12

Hold

-14.29%

Downside

Initiated

08/11/25

Tandem Diabetes downgraded to Hold from Buy at Lake StreetTandem Diabetes downgraded to Hold from Buy at Lake Street

Richard Newitter

Truist Financial

$17→$14

Hold

0.00%

Upside

Reiterated

08/07/25

Tandem Diabetes Care (TNDM) Receives a Hold from Truist Financial

Jeff Johnson

Robert W. Baird

$24→$16

Hold

14.29%

Upside

Reiterated

08/07/25

Robert W. Baird Remains a Hold on Tandem Diabetes Care (TNDM)

Matt Miksic

Barclays

$53→$51

Buy

264.29%

Upside

Reiterated

08/07/25

Tandem Diabetes Care (TNDM) Receives a Buy from Barclays

Christopher Pasquale

Nephron

$14

Hold

0.00%

Upside

Downgraded

08/07/25

Tandem Diabetes downgraded to Hold from Buy at Nephron ResearchTandem Diabetes downgraded to Hold from Buy at Nephron Research

Mike Kratky

Leerink Partners

$38→$32

Buy

128.57%

Upside

Reiterated

08/07/25

Positive Outlook for Tandem Diabetes Care: Buy Rating Reaffirmed Amid Growth Catalysts and Strategic Opportunities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tandem Diabetes Care

1 Month

xxx

Success Rate

14/21 ratings generated profit

Average Return

+5.28%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.28% per trade.

3 Months

xxx

Success Rate

10/21 ratings generated profit

Average Return

+1.54%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.62% of your transactions generating a profit, with an average return of +1.54% per trade.

1 Year

Matt MiksicBarclays

Success Rate

6/15 ratings generated profit

Average Return

-7.83%

reiterated a buy rating 2 months ago

Copying Matt Miksic's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -7.83% per trade.

2 Years

xxx

Success Rate

2/15 ratings generated profit

Average Return

-26.41%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 13.33% of your transactions generating a profit, with an average return of -26.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TNDM Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TNDM has received 11 Buy Ratings, 21 Hold Ratings, and 1 Sell Ratings. TNDM average Analyst price target in the past 3 months is 19.53.

Each month's total comprises the sum of three months' worth of ratings.

TNDM Financial Forecast

TNDM Earnings Forecast

Next quarter’s earnings estimate for TNDM is -$0.33 with a range of -$0.54 to -$0.07. The previous quarter’s EPS was -$0.48. TNDM beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year TNDM has Preformed in-line its overall industry.

TNDM Sales Forecast

Next quarter’s sales forecast for TNDM is $235.75M with a range of $233.21M to $240.04M. The previous quarter’s sales results were $240.68M. TNDM beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year TNDM has Preformed in-line its overall industry.

TNDM Stock Forecast FAQ

What is TNDM’s average 12-month price target, according to analysts?

Based on analyst ratings, Tandem Diabetes Care’s 12-month average price target is 19.53.

What is TNDM’s upside potential, based on the analysts’ average price target?

Tandem Diabetes Care has 39.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TNDM a Buy, Sell or Hold?

Tandem Diabetes Care has a consensus rating of Moderate Buy which is based on 7 buy ratings, 13 hold ratings and 0 sell ratings.

What is Tandem Diabetes Care’s price target?

The average price target for Tandem Diabetes Care is 19.53. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $51.00 ,the lowest forecast is $12.00. The average price target represents 39.50% Increase from the current price of $14.

What do analysts say about Tandem Diabetes Care?

Tandem Diabetes Care’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of TNDM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Tandem Diabetes Care (TNDM) Stock Forecast & Price Target

TNDM Analyst Ratings

TNDM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Tandem Diabetes Care

TNDM Analyst Recommendation Trends

TNDM Financial Forecast

TNDM Earnings Forecast

TNDM Sales Forecast

TNDM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts